<DOC>
	<DOCNO>NCT00312871</DOCNO>
	<brief_summary>The purpose study assess effect early complete correction anemia treatment epoetin alfa rate progression chronic renal failure ( involve improper function kidney ) . It also assess effect hemoglobin normalization ( correction anemia ) need renal ( kidney ) replacement therapy , quality life , blood pressure control , hospital admission , mortality , cardiovascular event , nutritional status safety .</brief_summary>
	<brief_title>Effects Early Correction Anemia Patients With Chronic Renal Insufficiency</brief_title>
	<detailed_description>Epoetin alfa increase hemoglobin level chronic renal failure patient ( patient persistent kidney dysfunction ) result minimal transfusion requirement improve kidney function capacity . This study randomize ( patient randomly divide group ) , multicenter , open-label ( study drug know patient ) clinical trial ass effect normalization hemoglobin ( defined hemoglobin level 13-14 g/dL woman 14-15 g/dL men ) rate progression chronic renal failure ( persistent kidney dysfunction ) . The study duration 40 month . The study two phase ( Phase A = stabilization , Phase B = maintenance ) two patient group ( Group 1 , Group 2 ) per phase . In Phase A ( last 4 month ) patient Group 1 , hemoglobin progressively increase target level . Phase A extended 6 month Group 1 patient target hemoglobin ( 13-14 g/dL woman , 14-15 g/dL men ) reach . Patients Group 2 , hemoglobin progressively increase 12 g/dL epoetin alfa drop 11 g/dL . For patient Phase A , Iron vitamin deficiency also correct , factor know affect progression renal failure ( kidney dysfunction ) optimize . In Phase B ( last 36 month ) , effectiveness anemia correction epoetin alfa compare non-correction ( continued anemia ) regard change kidney function . During phase , patient maintain high ( Group 1 ) low ( Group 2 ) target hemoglobin level . Safety data ( include cardiovascular event , seizure , hypertension ) collect monitor throughout study . The hypothesis study correction anemia may slow kidney deterioration progression kidney failure end-stage kidney disease cause anemia-induced hypoxia , state oxygen deficiency kidney . Another hypothesis study genetic mutation ( change gene ) may play role progression chronic renal failure . For patient wish participate aspect study , blood sample collect genomic DNA analysis result compile determine gene generally associate study population kidney deterioration . Patients receive epoetin alfa injection ( 25 100 IU/kg ) skin 1 time per week . Dosage may increase 25 IU/kg increment reach maintain target hemoglobin , dose maintain study duration , long hemoglobin stay within range .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Patients history chronic renal failure , least 6month followup least 3 measurement serum creatinine patient rate decline glomerular filtration rate ( GFRa measure kidney function ) 0.6 mL/min/month patient hemoglobin level &lt; 13 g/dL men &lt; 12.5 g/dL woman without active blood loss iron deficiency patient glomerular filtration rate ( measure kidney function ) 25 60 mL/min/1.73m2 ) patient blood pressure &lt; =160/100 mm Hg ( without antihypertensive therapy ) Patients chronic renal failure ( kidney dysfunction ) associate inherited polycystic kidney disease patient currently receive treatment epoetin anemia secondary chronic renal failure , hemoglobin level &gt; 11 g/dL patient receive epoetin hemoglobin level 11 g/dL exclude patient severe hypertension ( blood pressure &gt; = 180/110 mm Hg ) within 3 month prior study entry patient history New York Heart Association ( NYHA ) class III IV congestive heart failure within precede two year NYHA class I II congestive heart failure accept patient history ischemic heart disease ( deficient blood supply heart due constrict obstructed artery ) concurrent malignancy patient transfusion red blood cell within 30 day prior study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Chronic renal failure</keyword>
	<keyword>Anemia</keyword>
	<keyword>Renal replacement therapy</keyword>
	<keyword>Epoetin</keyword>
	<keyword>Epoetin alfa</keyword>
	<keyword>erythropoietin</keyword>
	<keyword>Chronic kidney failure</keyword>
	<keyword>end-stage renal disease</keyword>
</DOC>